35 results
Keyword Adrovance Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Adrovance
colecalciferol, alendronic acid (as sodium trihydrate), Osteoporosis, Postmenopausal
Date of authorisation: 04/01/2007, Revision: 25, Authorised, Last updated: 04/10/2023Adrovance Osteoporosis Bone Diseases … assessment report (EPAR) for Adrovance. It explains how the The committee … the conditions of use for Adrovance. What is Adrovance? Adrovance is a medicine that contains … -
List item
Press release: European Medicines Agency concludes class review of bisphosphonates and atypical fractures
CHMP, Last updated: 15/04/2011these referrals (Aclasta, Adrovance, Bondenza, Bondronat, Bonviva … these referrals (Aclasta, Adrovance, Bondenza, Bondronat, Bonviva … -
List item
Referral: Bisphosphonates
alendronic acid, clodronic acid, etidronic acid, ibandronic acid, neridronic acid, pamidronic acid, risedronic acid, tiludronic acid, zoledronic acid, associated names: Actonel, Aredia, Bonefos, Didronel, Fosamax, Nerixia, Skelid, Article 31 referrals
Status: European Commission final decision, opinion/position date: 14/04/2011, EC decision date: 13/07/2011, Last updated: 28/10/2011information Aclasta: EPAR Adrovance: EPAR Bondenza: EPAR Bondronat … Teva (ibandronic acid), and Adrovance and Fosavance (alendronic … these referrals (Aclasta, Adrovance, Bondenza, Bondronat, Bonviva … -
List item
National expert: ARIADNA TIBAU MARTORELL, The Spanish Agency Of Medicines And Medical Devices (updated)
- Declaration of interests - 40.71 KB | PDF
- Curriculum Vitae - 89.03 KB | PDF
-
List item
Human medicine European public assessment report (EPAR): Vantavo (previously Alendronate sodium and colecalciferol, MSD)
alendronic acid, colecalciferol, Osteoporosis, Postmenopausal
Date of authorisation: 16/10/2009, Revision: 18, Authorised, Last updated: 04/10/2023 -
List item
Human medicine European public assessment report (EPAR): Fosavance
alendronic acid, colecalciferol, Osteoporosis, Postmenopausal
Date of authorisation: 24/08/2005, Revision: 27, Authorised, Last updated: 04/10/2023 -
List item
National expert: Rui Castro, European Medicines Agency (updated)
- Declaration of interests - 40.48 KB | PDF
- Curriculum Vitae - 64.6 KB | PDF
-
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 27-30 November 2023 (updated)
European Medicines Agency, Amsterdam, the Netherlands, from 27/11/2023 to 30/11/2023, Last updated: 27/11/2023 -
List item
Committee for Medicinal Products for Human Use (CHMP): 24-26 April 2023
European Medicines Agency, Amsterdam, the Netherlands, from 24/04/2023 to 26/04/2023, Last updated: 07/07/2023 -
List item
Committee for Medicinal Products for Human Use (CHMP): 14-17 September 2020
Virtual meeting, from 14/09/2020 to 17/09/2020, Last updated: 10/03/2021 -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 30/11/2023 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 30 August – 2 September 2021
PRAC, Last updated: 17/09/2021 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 5-8 May 2014
European Medicines Agency, London, UK, from 05/05/2014 to 08/05/2014, Last updated: 13/08/2013 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 3-6 November 2014
European Medicines Agency, London, UK, from 03/11/2014 to 06/11/2014, Last updated: 13/08/2013 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 July 2014
European Medicines Agency, London, UK, from 07/07/2014 to 10/07/2014, Last updated: 13/08/2013 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 30 August-2 September 2021
European Medicines Agency, Amsterdam, the Netherlands, from 30/08/2021 to 02/09/2021, Last updated: 27/02/2018 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 5-8 February 2018
European Medicines Agency, London, UK, from 05/02/2018 to 08/02/2018, Last updated: 13/03/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 September 2015
European Medicines Agency, London, UK, from 07/09/2015 to 10/09/2015, Last updated: 13/03/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 4-8 July 2016
European Medicines Agency, London, UK, from 04/07/2016 to 08/07/2016, Last updated: 04/07/2016 -
List item
Press release: Meeting highlights from the Committee for Medicinal Products for Human Use,16-18 October 2006
CHMP, Last updated: 19/10/2006review time of 196 days. Adrovance (alendronic acid and colecalciferol … vitamin D insufficiency. Adrovance is the same medicinal product … -
List item
CHMP: Agendas, minutes and highlights (updated)
Last updated: 10/11/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 9-12 March 2015
European Medicines Agency, London, UK, from 09/03/2015 to 12/03/2015, Last updated: 13/03/2014 -
List item
EMA Human Scientific Committees' Working Parties with Patients' and Consumers' Organisations (PCWP) and Healthcare Professionals' Organisations (HCPWP) joint meeting: Workshop on social media
European Medicines Agency, London, UK, 19/09/2016, Last updated: 17/11/2016 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 30 August - 2 September 2016
European Medicines Agency, London, UK, from 30/08/2016 to 02/09/2016, Last updated: 13/03/2014 -
List item
Download medicine data
Last updated: 02/12/2021